Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Reassessing the association between circulating Vitamin D and IGFBP-3: observational and Mendelian randomization estimates from independent sources.

Tan VY, Biernacka KM, Dudding T, Bonilla C, Gilbert R, Kaplan RC, Qi Q, Teumer A, Martin RM, Perks CM, Timpson NJ, Holly JM.

Cancer Epidemiol Biomarkers Prev. 2018 Aug 2. pii: cebp.0113.2018. doi: 10.1158/1055-9965.EPI-18-0113. [Epub ahead of print]

PMID:
30072546
2.

Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2.

Biernacka KM, Persad RA, Bahl A, Gillatt D, Holly JM, Perks CM.

Endocr Relat Cancer. 2017 Jan;24(1):17-30. Epub 2016 Oct 17.

3.

Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2.

Biernacka KM, Uzoh CC, Zeng L, Persad RA, Bahl A, Gillatt D, Perks CM, Holly JM.

Endocr Relat Cancer. 2013 Sep 11;20(5):741-51. doi: 10.1530/ERC-13-0077. Print 2013 Oct.

4.

Role of the IGF axis in prostate cancer.

Biernacka KM, Perks CM, Holly JM.

Minerva Endocrinol. 2012 Jun;37(2):173-85. Review.

PMID:
22691890
5.

Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel.

Uzoh CC, Holly JM, Biernacka KM, Persad RA, Bahl A, Gillatt D, Perks CM.

Br J Cancer. 2011 May 10;104(10):1587-93. doi: 10.1038/bjc.2011.127. Epub 2011 Apr 12.

6.

Hyperglycaemia confers resistance to chemotherapy on breast cancer cells: the role of fatty acid synthase.

Zeng L, Biernacka KM, Holly JM, Jarrett C, Morrison AA, Morgan A, Winters ZE, Foulstone EJ, Shield JP, Perks CM.

Endocr Relat Cancer. 2010 May 18;17(2):539-51. doi: 10.1677/ERC-09-0221. Print 2010 Jun.

Supplemental Content

Loading ...
Support Center